Showing results (1881-1890 of 1,933) with videos related to

Sort By:
Pageof 194
British Journal of Cancer|April 28, 2025
Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapyE J van Dijk, H H Nienhuis, A J M van den Eertwegh, et al.
Melanoma Research|June 15, 2022
Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitorsRawa K Ismail, Karijn P M Suijkerbuijk, Anthonius de Boer, et al.
Cancers|July 2, 2021
Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint InhibitorsNienke A de Glas, Esther Bastiaannet, Frederiek van den Bos, et al.
European Journal of Cancer (Oxford, England : 1990)|December 29, 2020
Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registryM C T van Zeijl, L C de Wreede, A J M van den Eertwegh, et al.
Forensic Science, Medicine, and Pathology|November 13, 2021
High prevalence of non-accidental trauma among deceased children presenting at Level I trauma centers in the NetherlandsMarie-Louise H J Loos, Roel Bakx, Wilma L J M Duijst, et al.
International Journal of Cancer|June 26, 2024
Adjuvant treatment with anti-PD-1 in acral melanoma: A nationwide studyManja Bloem, Olivier J van Not, Maureen J B Aarts, et al.
Eclinicalmedicine|February 19, 2024
Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021Olivier J van Not, Alfons J M van den Eertwegh, John B Haanen, et al.
British Journal of Cancer|April 15, 2025
Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysisM Bloem, M M de Meza, A J M van den Eertwegh, et al.
ESMO Open|November 17, 2020
Lower risk of severe checkpoint inhibitor toxicity in more advanced diseaseRik J Verheijden, Anne M May, Christian U Blank, et al.
Melanoma Research|May 12, 2018
Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomesMaartje G Schouwenburg, Anouk Jochems, Brenda Leeneman, et al.
Pageof 194